U.S. markets closed

Navidea Biopharmaceuticals, Inc. (NAVB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.3000+0.0200 (+1.56%)
At close: 12:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.2800
Bid1.2600 x 1800
Ask1.3200 x 1000
Day's Range1.2600 - 1.3316
52 Week Range1.2100 - 3.1500
Avg. Volume59,725
Market Cap39.245M
Beta (5Y Monthly)1.72
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NAVB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Navidea Biopharmaceuticals, Inc
    Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 2Q21. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings, among others. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of activist investors, according to Vickers.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Zacks

    Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should Know

    Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    4 Penny Stocks Insiders Are Buying

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. LightPath Technologies The Trade: LightPath Technologies, Inc. (NASDAQ: LPTH) Chief Financial Officer Albert Miranda acqui

  • Zacks

    Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates

    Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?